Faculty Collaboration Database

CD23 expression in follicular lymphoma: clinicopathologic correlations. Am J Clin Pathol 2011 Jan;135(1):46-53

Date

12/22/2010

Pubmed ID

21173123

DOI

10.1309/AJCP27YWLIQRAJPW

Scopus ID

2-s2.0-79251510889 (requires institutional sign-in at Scopus site)   31 Citations

Abstract

Follicular lymphoma (FL) is typically a CD10+/CD5-/FMC-7+ B-cell lymphoma with variable CD23 expression. The clinical significance of CD23 expression in FL is uncertain. We studied the expression of CD23 by flow cytometry in 69 lymph nodes (LNs) and correlated it with pathologic and clinical parameters. Of 69 FLs, 48 (70%) were CD23+. Grade 3 FLs were CD23- more often (12/16 [75%]) than grade 1 and 2 cases (9/53 [17%]; P < .001). CD23 expression was more common in FLs in inguinal LNs than in other sites: 20 of 23 (87%) vs 28 of 46 (61%; P = .029). Overall survival (P = .002) and event-free survival (P < .0001) were longer in the CD23+ group than in the CD23- FLs. Our study shows that grade 3 FLs are more often CD23- than lower grade FLs and that FLs in inguinal LNs are more frequently CD23+ than in LNs from other sites. Furthermore, our findings also indicate that survival is significantly better in CD23+ FLs.

Author List

Olteanu H, Fenske TS, Harrington AM, Szabo A, He P, Kroft SH

Authors

Timothy Fenske MD Professor in the Medicine department at Medical College of Wisconsin
Alexandra M. Harrington MD Professor in the Pathology department at Medical College of Wisconsin
Steven Howard Kroft MD Chair, Professor in the Pathology department at Medical College of Wisconsin
Aniko Szabo PhD Professor in the Institute for Health and Equity department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
Female
Flow Cytometry
Humans
Immunophenotyping
Lymph Nodes
Lymphoma, Follicular
Male
Middle Aged
Neoplasm Staging
Receptors, IgE
Survival Rate
Wisconsin